Tumour–brain crosstalk restrains cancer immunity via a sensory–sympathetic axis
Summary
This Nature paper shows that lung adenocarcinomas (LUAD) recruit and activate specific vagal sensory neurons (VSNs) — a NPY2R/TRPV1-enriched population — which relay tumour-derived signals to brainstem rostral ventrolateral medulla (RVLM) neurons. That brain activation increases sympathetic output to the lung, raising local noradrenaline levels. Noradrenaline acts via β2-adrenergic receptor (ADRB2) on alveolar macrophages to drive an ARG1+ immunosuppressive phenotype that restrains tumour-reactive T cells and thereby promotes tumour growth.
In mice, selective ablation or chemogenetic silencing of tumour-innervating VSNs reduced tumour burden, boosted intratumoural CD8 and CD4 T cell responses and lowered ARG1 in alveolar macrophages. Blocking the VSN→RVLM→sympathetic axis (genetically or chemogenetically) or deleting ADRB2 in haematopoietic cells reproduced the tumour-suppressive, immune-stimulatory effects. Conversely, inhaled β2 agonist (salbutamol) reversed the benefit of VSN ablation. Analysis of TCGA LUAD cohorts showed that high combined VSN and sympathetic gene signatures correlate with worse survival and lower CD8 T cell infiltration.
Key Points
- LUAD lesions are densely innervated by vagal sensory fibres; tumour-derived neurotrophic factors (for example NGF) promote VSN outgrowth.
- A specific lung-innervating VSN subset (NPY2R+/TRPV1+) promotes tumour growth; ablation or silencing of these neurons suppresses LUAD in mice.
- VSN activity transmits to the brainstem (NTS→RVLM), increasing sympathetic efferent activity and noradrenaline in the tumour microenvironment.
- Noradrenaline acts via ADRB2 on alveolar macrophages to upregulate ARG1 and suppress tumour-reactive CD4/CD8 T cells.
- Genetic loss of ADRB2 in haematopoietic cells, or selective ADRB2 deletion in alveolar macrophages, enhances anti-tumour immunity and lowers tumour burden.
- Pharmacological activation of ADRB2 (inhaled salbutamol) restores tumour growth in VSN-ablated mice, showing the pathway is necessary and sufficient.
- Human LUAD data: high combined VSN + sympathetic signature associates with poorer survival and reduced CD8 T cell signatures — suggesting clinical relevance and possible benefit from adrenergic blockade.
Why should I read this?
Short version: tumours are literally talking to your brain via vagal sensory nerves — and that chit-chat ramps up sympathetic signals that switch lung macrophages into a T cell-squelching mode. If you care about why some lung cancers dodge immunity (or whether beta-blockers could help), this paper gives you the neural circuit and cellular mechanism in one tidy package.
Author style
Punchy: This is a high-impact mechanistic story tying tumour-derived cues, a defined vagal sensory neuron subtype, a brainstem sympathetic relay and macrophage ADRB2 signalling to immune evasion. The data are broad (genetics, chemogenetics, imaging, scRNA-seq, TCGA) and point to actionable nodes — worth digging into if you work on tumour immunology, neuro-immune cross-talk or translational strategies for lung cancer.
Context and relevance
The study integrates cancer neuroscience and tumour immunology: instead of only focusing on local tumour factors, it defines a bidirectional tumour–brain loop that actively shapes the tumour microenvironment. The identification of VSN→RVLM→sympathetic→ADRB2(on alveolar macrophages) as a pathway that dampens anti-tumour T cells suggests new therapeutic angles (neural modulation, beta-adrenergic blockade, targeting macrophage ADRB2) and helps explain retrospective clinical signals linking beta-blocker use to improved outcomes in NSCLC.